17 August 2016 - It’s easy to point a finger at the US and blame the pharmaceutical companies’ lawyers for creating such a system and at times gaming it (eg. pay-for-delay deals).

In an article pubished in Regulatory Focus, Jacob Sherkow, an associate professor in intellectual property law at New York Law School, argues that the length of US market exclusivity is one of the reasons why so many companies want to introduce their treatments in the US first (and why new drugs generally reach the market in the US more quickly than elsewhere).

Read Regulatory Focus article